Endocrine disrupting chemicals (EDCs) have widespread environmental distribution
originated from both natural and anthropogenic sources. From the last few decades, their …

Simple Summary Differentiation syndrome (DS) is a frequent clinical complication of
treatment with all-trans retinoic acid (ATRA) and/or arsenic trioxide (ATO), and is typically …

The introduction of all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) has transformed
the outcome of acute promyelocytic leukemia (APL) from a uniformly fatal disease to one of …

Arsenic trioxide (ATO) is the backbone of acute promyelocytic leukemia (APL) treatment and
is dosed based on weight with no upper limit, therefore obese patients receive large doses …

The hallmark of acute promyelocytic leukemia (APL) is the presence of the characteristic
fusion transcript of the promyelocytic leukemia gene with the retinoic acid receptor α gene …

The article presents a case study of a 12-year-old female presented to our hospital with
spots of subcutaneous bleeding that had been present for 1 week. Topics include the …

In all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) treatment of acute promyelocytic
leukemia (APL), differentiation syndrome (DS) assumes a distinct identity separate from …

A 55-year-old woman developed acute promyelocytic leukaemia during treatment with all-
trans-retinoic acid and arsenic trioxide. Initially, she presented with symptoms of epigastric …

In acute promyelocytic leukemia (APL) potentially fatal coagulopathy and hemorrhages
remain major causes of induction failure. Serious thrombotic events are frequently reported …

Ölümcül koagulopatiler ve hemorajiler akut promiyelositik lösemide (APL) indüksiyon
tedavisine yanıt alınamamasının temel sebeplerini oluşturmaktadır. Ağır trombotik olaylar …